12.57

1.45% 0.18

After Hours: 12.57

Myriad Genetics Inc (MYGN)

Overview News Price History Option Chain Financials Why MYGN Down? Discussions Forecast Stock Split

Myriad Genetics Inc stock is traded at $12.57, with a volume of 1.14M. It is up +1.45% in the last 24 hours and down -5.91% over the past month. Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Previous Close:

$12.39

Open:

$12.5

24h Volume:

1.14M

Relative Volume:

1.22

Market Cap:

$1.14B

Revenue:

$823.60M

Net Income/Loss:

$-116.00M

P/E Ratio:

-9.6692

EPS:

-1.3

Net Cash Flow:

$-107.30M

1W Performance:

-8.11%

1M Performance:

-5.91%

6M Performance:

-51.60%

1Y Performance:

-38.11%

1-Day Range:

$12.39

$12.77

1-Week Range:

$12.17

$14.31

52-Week Range:

$12.17

$29.30

Myriad Genetics Inc Stock (MYGN) Company Profile

Name

Myriad Genetics Inc

Sector

Healthcare (1176)

Industry

Diagnostics & Research (59)

Phone

801-584-3600

Address

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Employee

2,700

Twitter

@myriadgenetics

Next Earnings Date

2024-11-07

Latest SEC Filings

MYGN's Discussions on Twitter

Compare MYGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MYGN Myriad Genetics Inc	12.57	1.14B	823.60M	-116.00M	-107.30M	-1.30
TMO Thermo Fisher Scientific Inc	573.06	219.20B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	244.11	176.31B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	152.57	43.57B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	205.69	37.33B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	427.33	34.99B	3.84B	866.24M	792.60M	10.37

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-24	Initiated	UBS	Neutral
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Underperform
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform
Dec-21-23	Resumed	Piper Sandler	Neutral
Dec-19-23	Initiated	Wells Fargo	Equal Weight
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Jul-05-23	Resumed	JP Morgan	Underweight
May-23-23	Upgrade	Goldman	Sell → Buy
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform
Oct-06-22	Initiated	Stephens	Equal-Weight
Oct-15-21	Resumed	Cowen	Market Perform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy
Jan-03-19	Initiated	Needham	Strong Buy
Nov-30-18	Upgrade	Goldman	Sell → Neutral
Oct-10-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-11-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-21-18	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-29-18	Initiated	Goldman	Sell
Jan-22-18	Reiterated	Barclays	Equal Weight
Jan-05-18	Initiated	BTIG Research	Buy
Oct-02-17	Resumed	Leerink Partners	Mkt Perform
Aug-09-17	Reiterated	Barclays	Equal Weight
Feb-08-17	Upgrade	Ladenburg Thalmann	Sell → Neutral
Jan-18-17	Initiated	Deutsche Bank	Sell
Oct-10-16	Downgrade	Ladenburg Thalmann	Neutral → Sell

View All

Myriad Genetics Inc Stock (MYGN) Latest News

Jan 21, 2025

Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan

Jan 21, 2025

Jan 20, 2025

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN

Jan 20, 2025

Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research - GlobeNewswire Inc.

Jan 20, 2025

Jan 19, 2025

Myriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings Guidance - MarketBeat

Jan 19, 2025

Jan 17, 2025

Stephens Reaffirms Equal Weight Rating for Myriad Genetics (NASDAQ:MYGN) - MarketBeat

Jan 17, 2025

Myriad Genetics stock hits 52-week low at $12.85 amid market challenges - Investing.com Australia

Jan 17, 2025

Jan 16, 2025

RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq

Jan 16, 2025

Myriad Genetics: Navigating Through A Setback (NASDAQ:MYGN) - Seeking Alpha

Jan 16, 2025

Brokerages Set Myriad Genetics, Inc. (NASDAQ:MYGN) Target Price at $24.27 - MarketBeat

Jan 16, 2025

Jan 15, 2025

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance - The Manila Times

Jan 15, 2025

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial ... - The Bakersfield Californian

Jan 15, 2025

Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025 - Marketscreener.com

Jan 15, 2025

Jan 14, 2025

Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6%Here's What Happened - MarketBeat

Jan 14, 2025

Jan 13, 2025

Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN

Jan 13, 2025

Relationship Genetic Tests Market Report 2024, Featuring - GlobeNewswire

Jan 13, 2025

Relationship Genetic Tests Market Report 2024, Featuring Profiles of Laboratory Corporation of America, Quest Diagnostics, Cleveland Clinic, Myriad Genetics, Invitae and More - Yahoo Finance

Jan 13, 2025

Myriad Genetics FY2024 EPS Estimate Increased by Scotiabank - MarketBeat

Jan 13, 2025

Jan 11, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Acquired by Nordea Investment Management AB - MarketBeat

Jan 11, 2025

Jan 10, 2025

MYGN Stock Gains Following Collaboration With Hannah Storm - Yahoo Finance

Jan 10, 2025

Jan 09, 2025

Myriad Genetics (NASDAQ:MYGN) Rating Increased to Buy at StockNews.com - MarketBeat

Jan 09, 2025

Myriad Genetics Partners with ESPN's Hannah Storm to Champion Breast Cancer Risk Testing - StockTitan

Jan 09, 2025

PARP Inhibitor Biomarkers Market Review 2024 and Forecast 2025-2035: Breast Cancer Applications Lead in Revenue, While Ovarian Cancer Emerges as the Fastest-Growing Opportunity - Yahoo Finance UK

Jan 09, 2025

Jan 08, 2025

Myriad Genetics and MD Anderson Launch Strategic Partnership to Advance MRD Assays - Zenopa

Jan 08, 2025

UPDATEMyriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 08, 2025

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - StockTitan

Jan 08, 2025

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 08, 2025

Myriad Genetics to Present at J.P. Morgan Healthcare Conference 2024 with Live Webcast - StockTitan

Jan 08, 2025

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued - Simply Wall St

Jan 08, 2025

Jan 07, 2025

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay - MD Anderson Cancer Center

Jan 07, 2025

MD Anderson, Myriad Genetics Partner on Revolutionary Cancer Detection Technology - StockTitan

Jan 07, 2025